Tang, Lingling
Jiang, Yingan
Zhu, Mengfei
Chen, Lijun
Zhou, Xiaoyang
Zhou, Chenliang
Ye, Peng
Chen, Xiaobei
Wang, Baohong
Xu, Zhenyu
Zhang, Qiang
Xu, Xiaowei
Gao, Hainv
Wu, Xiaojun
Li, Dong
Jiang, Wanli
Qu, Jingjing
Xiang, Charlie
Li, Lanjuan
Article History
Received: 26 April 2020
Accepted: 10 June 2020
First Online: 6 August 2020
Compliance with ethics guidelines
: Lingling Tang, Yingan Jiang, Mengfei Zhu, Lijun Chen, Xiaoyang Zhou, Chenliang Zhou, Peng Ye, Xiaobei Chen, Baohong Wang, Zhenyu Xu, Qiang Zhang, Xiaowei Xu, Hainv Gao, Xiaojun Wu, Dong Li, Wanli Jiang, Jingjing Qu, Charlie Xiang, and Lanjuan Li declare no conflicts of interest. This study was approved by the Ethics Committee of Shulan (Hangzhou) hospital, Hangzhou, China and the Ethics Committee of Renmin Hospital of Wuhan University (No. WDRY2020-K011), Wuhan, China. MSC administration in patients with SARS-CoV-2 induced ARDS was conducted in a multi-center and open-label clinical trial (No. ChiCTR2000029606).
Free to read: This content has been made available to all.